Kymera Therapeutics recently appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, and the company was added to multiple Russell value and small-cap ...
Source LinkKymera Therapeutics recently appointed Elizabeth Laws, Ph.D., as Senior Vice President and KT-621 Development Program Leader, and the company was added to multiple Russell value and small-cap ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.